Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Viral Conjunctivitis - Overview Viral Conjunctivitis - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Viral Conjunctivitis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Viral Conjunctivitis - Companies Involved in Therapeutics Development Adenovir Pharma AB NanoViricides Inc Panoptes Pharma GesmbH Shire Plc Viral Conjunctivitis - Drug Profiles APD-209 - Drug Profile Product Description Mechanism Of Action R&D Progress APD-514 - Drug Profile Product Description Mechanism Of Action R&D Progress EKCCide-I - Drug Profile Product Description Mechanism Of Action R&D Progress OKG-0301 - Drug Profile Product Description Mechanism Of Action R&D Progress PP-001 - Drug Profile Product Description Mechanism Of Action R&D Progress SHP-640 - Drug Profile Product Description Mechanism Of Action R&D Progress Viral Conjunctivitis - Dormant Projects Viral Conjunctivitis - Discontinued Products Viral Conjunctivitis - Product Development Milestones Featured News & Press Releases Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Viral Conjunctivitis, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Viral Conjunctivitis - Pipeline by Adenovir Pharma AB, H2 2017 Viral Conjunctivitis - Pipeline by NanoViricides Inc, H2 2017 Viral Conjunctivitis - Pipeline by Panoptes Pharma GesmbH, H2 2017 Viral Conjunctivitis - Pipeline by Shire Plc, H2 2017 Viral Conjunctivitis - Dormant Projects, H2 2017 Viral Conjunctivitis - Discontinued Products, H2 2017

Adenovir Pharma AB NanoViricides Inc Panoptes Pharma GesmbH Shire Plc